← SearchSUBCLONAL HYPERMUTATION AS A DRIVER OF THERAPY RESISTANCE IN HER2+/ER+ BREAST CANCER$577,671FY2020Defense Health AgencyDODGeorgetown University, Washington DCInvestigatorsView source on USAspending →